Health insurers and corporate wellness programs are restructuring pharmacy benefit guidelines in response to expanded clinical indications for GLP-1 receptor agonists.
Actuarial Re-evaluations
Long-term actuarial models suggest potential cost offsets in cardiac care, though high upfront prescription costs present immediate cash-flow friction for mid-sized self-insured employers.